Retrophin paid Mar­tin Shkre­li 'undis­closed sum' to set­tle years­long le­gal dis­putes

Re­mem­ber when Retrophin dis­closed in June that it’s fi­nal­ly set­tled up the four-year le­gal saga with founder and for­mer CEO Mar­tin Shkre­li? In an up­date for in­vestors on Wednes­day, the com­pa­ny added that it had paid an undis­closed sum to the in­fa­mous biotech ex­ec and fi­nancier as part of the agree­ment — though it won’t say how much.

Shkre­li, who’s serv­ing a 7-year prison sen­tence for de­fraud­ing in­vestors of his hedge funds, had “agreed to ex­tin­guish his rights to fu­ture ad­vance­ment of le­gal fees and in­dem­ni­fi­ca­tion by the com­pa­ny (oth­er than for cer­tain pend­ing lit­i­ga­tion), and to abide by cer­tain stand­still re­stric­tions,” the com­pa­ny added in a 10-Q fil­ing first re­port­ed by CN­BC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER